Image

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Exploring new treatment for certain recurrent or hard-to-treat tumors.

Recruiting
12-39 years
All
Phase 2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study is exploring a treatment called trastuzumab deruxtecan for specific cancers: osteosarcoma (a bone cancer), Wilms tumor (a kidney cancer in children), and desmoplastic small round cell tumor (a rare cancer in the abdomen). This treatment is a combination of a targeted drug (an antibody) and chemotherapy. The antibody aims specifically at cancer cells that have a protein called HER2.

  • Study Length: Treatment is given every 21 days for up to 35 cycles, with follow-up after 6 months.
  • Visits Required: Patients will receive the drug through an IV and need regular scans and tests.
  • Eligibility: Participants include children and young adults with these cancers who haven't responded to previous treatments.

Participants will be continuously monitored for side effects and the effectiveness of the treatment. It's important for families to consider the duration of the study and the need for regular hospital visits. Compensation details are not provided, and potential risks include typical side effects from chemotherapy and targeted treatments.

Print
Study details
    Desmoplastic Small Round Cell Tumor
    Osteosarcoma
    Recurrent Desmoplastic Small Round Cell Tumor
    Recurrent Kidney Wilms Tumor
    Recurrent Osteosarcoma
    Refractory Desmoplastic Small Round Cell Tumor
    Refractory Wilms Tumor
    Wilms Tumor

NCT04616560

National Cancer Institute (NCI)

17 October 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race*
Are you a healthy volunteer
Ethnicity*
Are you a healthy volunteer
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.